This review aimed to assess the impact of okra (Abelmoschus esculentus L.) consumption on CVD risk factors. Relevant studies were identified through electronic searches of databases, including PubMed, Scopus, Web of Science, CENTRAL and EMBASE, up to January 2025. Twelve trials involving 770 participants with interventions ranging from 2 to 12 weeks and doses varying from 125 to 40 000 mg/d were included. Okra supplementation significantly reduced BMI (standardised mean difference (SMD) = −0·70; 95 % CI −1·23, −0·16; P = 0·011), fat mass (SMD = −0·74; 95 % CI −1·13, −0·36; P < 0·001), hip circumference (SMD = −0·85; 95 % CI −1·41, −0·28; P = 0·003), weight (SMD = −0·77; 95 % CI −1·42, −0·11; P = 0·022), fasting insulin (SMD = −0·35; 95 % CI −0·63, −0·07; P = 0·013), fasting plasma glucose (SMD = −1·07; 95 % CI −1·75, −0·38; P = 0·002), HbA1c (SMD = −0·38; 95 % CI −0·71, −0·05; P = 0·023), homeostatic model assessment of insulin resistance (SMD = −0·56; 95 % CI −0·84, −0·29; P < 0·001), LDL-cholesterol (SMD = −0·32; 95 % CI −0·52, −0·11; P = 0·003), total cholesterol (SMD = −0·45; 95 % CI −0·74, −0·16; P = 0·003) and aspartate aminotransferase (SMD = −0·45; 95 % CI −0·73, −0·17; P = 0·002). Okra supplementation demonstrated significant benefits in improving anthropometric measures, glycaemic control, lipid profiles and liver function tests, suggesting its potential as an adjunct therapy for improving CVD risk factors.